Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Austria / NCT07176338
Active, not recruiting Not applicable

Role of Metformin in Posterior Capsule Opacification

NCT07176338 · tracked via the Priya Life Science Austria tracker
Sponsor
Vienna Institute for Research in Ocular Surgery
Phase
Not applicable
Started
2022-10-12
Last updated
2025-09-16

Condition(s) studied

CataractDiabetes Mellitus Type 2

Investigational drug(s) / intervention(s)

Blood and lens capsule samples for PK testing

Blood and lens capsule samples for PK testing: Blood samples and lens capsule tissue will be collected from patients for PK testing

Study summary

Determination of concentrations of systemically applied metformin in human lens capsule and its ability to lower the proliferation rate of human lens epithelial cells in vitro.

Eligibility

Sex
ALL
Min age
21 Years
Max age
105 Years
Healthy volunteers
No
Inclusion Criteria: * Age-related cataract * Diabetes mellitus type II * Metformin treatment * Age 21 or older * Written informed consent prior to surgery Exclusion Criteria: * Diabetes mellitus type I * Previous ocular surgery or trauma regarding cataract surgery * Previous vitrectomy * Pregnancy (pregnancy test will be taken in women of reproductive age)

Primary outcome measure(s)

  • Metformin concentration in the human lens capsule — 12 months

Trial sites (1)

FacilityCityRegionStatus
Vienna Institute for Research in Ocular Surgery (VIROS) Vienna Austria

More Vienna Institute for Research in Ocular Surgery trials in Austria

Eyelid Closure in Keratometry Recruiting
Brillouin Microscopy Used to Evaluate Corneal Mechanical Properties Starting soon
Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration Active, not recruiting
Visual Function of Enhanced Monofocal Intraocular Lenses Starting soon
Detection of Keratoconus Progression Using Machine Learning Active, not recruiting

Other trials for the same condition

Automated Insulin Delivery Versus Daily Injections for Hospital Diabetes Care Starting soon
Evaluation of Microinvasive Glaucoma Surgery: MINIject® Versus Hydrus® Microstent in Combination With Cataract Surgery Recruiting
Pseudophakic Eyes With Presbyopia-correcting IOLs: OCT Biometry and Pyramid Aberrometry Recruiting
Brillouin Scanning in Cataractous Eyes Active, not recruiting
Intraocular Lens Calculation Using Artificial Intelligence Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07176338 on ClinicalTrials.gov ↗ ← All trials in Austria